UBS Maintains a 'Neutral' on SXC Health Solutions (SXCI); Mgmt Believes All Cylinders in Place Thru 2015

UBS maintains a 'Neutral' on SXC Health Solutions (NASDAQ: SXCI) price target raised from $45 to $49.

UBS analyst says, "SXCI continues to leverage its operating platform for growth with revs of $1,287 mil (+$80-100 mil vs. UBSe/Street) translating to cash EPS of $0.44 (+$0.01-0.02 vs. UBSe/Street). The sequential uptick in claim volume to 23.3 mil allayed any lingering concerns on soft pharma utilization. Given the positive outlook for SXCI in relation to both the 2012 and 2013 selling seasons, the company remains on a rapid organic growth curve with or without HealthSpring (NYSE: HS)."

"...We are raising our 2012 Cash EPS estimate to $2.24 (vs. prior $2.05) to include PTRx deal close and new business wins, while maintaining HealthSpring/Bravo contract (from 2011-15)."

For more ratings news on SXC Health Solutions click here and for the rating history of SXC Health Solutions click here.

Shares of SXC Health Solutions closed at $47.53 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
• B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral